These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1205336)

  • 1. Photometric assay of antithrombin III with a chromogenic substrate.
    Vinazzer H
    Haemostasis; 1975; 4(2):101-9. PubMed ID: 1205336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photometric assay of platelet factor 4 with a chromogenic substrate.
    Vinazzer H
    Haemostasis; 1977; 6(5):283-93. PubMed ID: 598749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombin III: a backward glance o'er travel'd roads.
    Seegers WH
    Adv Exp Med Biol; 1975; 52():195-215. PubMed ID: 47704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods for semi micro or automated determination of thrombin, antithrombin, and heparin cofactor using he substrate, H-D-Phe-Pip-Arg-p-nitroanilide-2HCl.
    Scully MF; Kakkar VV
    Clin Chim Acta; 1977 Sep; 79(3):595-602. PubMed ID: 70286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proceedings: Photometric assay of antithrombin III with a chromogenic substrate.
    Vinazzer H
    Thromb Diath Haemorrh; 1975 Sep; 34(1):344-5. PubMed ID: 1188785
    [No Abstract]   [Full Text] [Related]  

  • 6. A simple amidolytic method for the determination of functional active antithrombin III.
    Abildaard U; Lie M; Odegård OR
    Scand J Clin Lab Invest; 1976 Jan; 36(1):109-12. PubMed ID: 815998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the biological activity of heparin by use of a chromogenic substrate.
    Bartl K; Dorsch E; Lill H; Ziegenhorn J
    Thromb Haemost; 1980 Feb; 42(5):1446-51. PubMed ID: 7368151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A method for the differential determination of plasma antithrombins.
    Musumeci V; Vincenti A; Bizzi B
    J Clin Pathol; 1976 Jan; 29(1):63-8. PubMed ID: 55420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heparin assay in plasma. Comparison of different methods (author's transl)].
    Vinazzer H
    Anaesthesist; 1979 Jun; 28(6):299-303. PubMed ID: 464252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays.
    Beeck H; Nagel D; Pindur G; Scharrer I; Preiss A; Seiler D; Hellstern P
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):127-35. PubMed ID: 10759005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of thrombin and plasmin to heparin and antithrombin III.
    Bauer PI; Breuer Z; Machovich R; Büki KG; Horváth I
    Acta Biochim Biophys Acad Sci Hung; 1985; 20(3-4):155-61. PubMed ID: 2944348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombin III. Theory and clinical applications. H. P. Smith Memorial Lecture.
    Seegers WH
    Am J Clin Pathol; 1978 Apr; 69(4):299-359. PubMed ID: 347919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
    Berry CN; Girardot C; Lecoffre C; Lunven C
    Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
    Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
    J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standardisation of a simple method for the determination of antithrombin activity.
    Frigola A
    J Clin Pathol; 1977 Sep; 30(9):881-3. PubMed ID: 915017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
    Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
    J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a new laboratory test to evaluate antithrombin resistance in plasma.
    Murata M; Takagi A; Suzuki A; Okuyama E; Takagi Y; Ando Y; Kato I; Nakamura Y; Murate T; Matsushita T; Saito H; Kojima T
    Thromb Res; 2014 Feb; 133(2):293-8. PubMed ID: 24325876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse effect of heparin in thrombin-antithrombin III interaction.
    Marciniak E
    Thromb Diath Haemorrh; 1975 Dec; 34(3):748-62. PubMed ID: 1209544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.